Antimicrobial resistance in ESKAPE pathogens
Antimicrobial-resistant ESKAPE (E nterococcus faecium, S taphylococcus aureus, K
lebsiella pneumoniae, A cinetobacter baumannii, P seudomonas aeruginosa, and E …
lebsiella pneumoniae, A cinetobacter baumannii, P seudomonas aeruginosa, and E …
New β-lactam–β-lactamase inhibitor combinations
D Yahav, CG Giske, A Grāmatniece… - Clinical microbiology …, 2020 - Am Soc Microbiol
The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …
[HTML][HTML] Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa
isolates are frequent causes of serious nosocomial infections that may compromise the …
isolates are frequent causes of serious nosocomial infections that may compromise the …
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections
In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
[HTML][HTML] The “old” and the “new” antibiotics for MDR gram-negative pathogens: for whom, when, and how
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …
significant challenges in the treatment of healthcare associated infections. An important …
[HTML][HTML] Treatment of infections due to MDR Gram-negative bacteria
M Bassetti, M Peghin, A Vena, DR Giacobbe - Frontiers in medicine, 2019 - frontiersin.org
The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in
critically ill patients presents many challenges. Since an effective treatment should be …
critically ill patients presents many challenges. Since an effective treatment should be …
Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority …
MH Kollef, M Nováček, Ü Kivistik… - The Lancet Infectious …, 2019 - thelancet.com
Background Nosocomial pneumonia due to antimicrobial-resistant pathogens is associated
with high mortality. We assessed the efficacy and safety of the combination antibacterial …
with high mortality. We assessed the efficacy and safety of the combination antibacterial …
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa
Background Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor
combination that often retains activity against resistant Pseudomonas aeruginosa. The …
combination that often retains activity against resistant Pseudomonas aeruginosa. The …
[HTML][HTML] New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review
P. aeruginosa is still one of the most threatening pathogens responsible for serious hospital-
acquired infections. It is intrinsically resistant to many antimicrobial agents and additional …
acquired infections. It is intrinsically resistant to many antimicrobial agents and additional …
[HTML][HTML] New antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia
M Bassetti, A Mularoni, DR Giacobbe… - … in respiratory and …, 2022 - thieme-connect.com
Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent
one of the most common hospital-acquired infections, carrying a significant morbidity and …
one of the most common hospital-acquired infections, carrying a significant morbidity and …